Magda Wierzycka is the co-founder and chief executive officer of asset management group Sygnia. Wierzycka began her career as a product development and investments actuary at Southern Life in 1993, and then worked as an investment consultant for two years at Alexander Forbes. In 1997, she joined Coronation Fund Managers, which she then left six years later to start IQvest, a fund of hedge funds management company. Later that year, after selling IQvest to the African Harvest group, she was appointed to the position of CEO of African Harvest. After negotiating the sale of African Harvest Fund Managers to Cadiz Financial Services in 2006, Wierzycka led the management buy-out of the remainder of the African Harvest group, which resulted in the formation of Sygnia. Today, Sygnia has in excess of R250 billion in assets under management and administration, and is listed on the Johannesburg Stock Exchange. In this episode of Business Talk with Michael Avery, Wierzycka discusses the global challenges brought on by the prolonged Covid-19 pandemic, including travel restrictions and the impact of various lockdowns. Currently in London, Wierzycka talks through South Africa’s approach in obtaining a vaccine – with detailed knowledge in this regard, having set up a venture-capital company called Bravos which has investments in two companies involved in the development of Covid vaccines, including AstraZeneca. Wierzycka talks Michael through vaccine development, testing, and market readiness, highlighting the challenges around the South African variant, while also providing some insight into the rollout of a vaccine to citizens in the UK. The full interview is embedded below. You can find all the Business Talk with Michael Avery interviews here. <span style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" data-mce-type="bookmark" class="mce_SELRES_start">﻿</span>